Patient leaflet - ONDANSETRON 4 MG ORODISPERSIBLE TABLETS
Package leaflet:
Ondansetron 4 mg orodispersible tablets Ondansetron 8 mg orodispersible tablets ondansetron nouJsS.li!!
Ondansetron Bluefish orodispersible tablets contain aspartame, glucose, maltodextrin, sorbitol, sulphur dioxide and sodium
orodispersible tablet and 1.76 mg aspartame in
each 8 mg orodispersible tablet.
Aspartame is a source of phenylalanine. It may be
because the body cannot remove it properly.
Ondansetron orodispersible tablets contain glucose and maltodextrin. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
May be harmful to the teeth.
Ondansetron Bluefish orodispersible tablets contain sorbitol (E 420). This medicine contains 8.4 mg sorbitol in each 4 mg orodispersible tablet and 16.98 mg sorbitol in each 8 mg orodispersible tablet.
Ondansetron orodispersible tablets contain sulphur dioxide (E 220). May rarely cause severe hypersensitivity reactions and bronchospasm.
Ondansetron Bluefish orodispersible tablets contain sodium. This medicine contains less than 1 mmol sodium (23 mg) per orodispersible tablet, that is to say essentially ‘sodium-free’.
Laetus reading direction
3. how to take ondansetron orodispersible tablets
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
After starting to take your medicine
Ondansetron orodispersible tablets should start to work within one or two hours of taking a dose. If you are sick within one hour of taking a dose, then take the same dose again -otherwise do not take more Ondansetron orodispersible tablets than the label says. If you continue to feel sick then tell your doctor.
Treatment and prevention of nausea and vomiting in connection with chemotherapy or radiotherapy
Adults:
8 mg 1 to 2 hours before chemotherapy or radiotherapy followed by 8 mg 12 hours for up to 5 days. Your doctor may decide to give the first dose as an injection.
Elderly:
The same dose as for adults.
Use in Children (age 2 years and up) and adolescents under the age of 18 years:
The dose is individual and depends on the size/surface of the child. Ondansetron Bluefish should not be used for children with a total body surface of less than 0.6 m .
Children aged over 6 months and adolescents
- The usual dose for a child is up to 4 mg twice a day
- This can be given up to 5 days
Treatment and prevention of post-operative nausea and vomiting
Adults, prevention and treatment:
16 mg one hour prior to anaesthesia or alternatively, 8 mg administered one hour prior to anaesthesia followed by an additional 8 mg after 8 and 16 hours. Your doctor may choose to give you the medicine as injections.
Elderly, prevention and treatment:
There is limited experience with the use of ondansetron to elderly patients. Ondansetron is however tolerated well by patients above 65 years in chemotherapy (please refer to section above).
Patients with moderate or severe liver disease : the total daily dose should not be more than 8 mg.
Patients with poor sparteine/debrisoquine metabolism: No alteration of daily dosage or frequency of dosing is required.
The tablets must be taken as follows :
Do not remove Ondansetron Bluefish orodispersible tablets from its blister or pierce the foil until you are ready to take it.
In order to prevent the breakage of tablets, it is important not to push the tablet out of its recess (Figure A).
The tablets in each strip are separated from each other by perforations. Detach one tablet recess along the perforation (Figure 1). The covering foil should be removed carefully. Start with the corner that is marked with an arrow (Figures 2 and 3).
The tablet must be taken from the container with dry hands and placed on the tongue (Figure 4). The tablet will disintegrate, after which it can be swallowed with water.
150 mm
Figure A. Figure 1. Figure 2.
Do not use this medicine after the expiry date which is stated on the carton or foil after EXP. The expiry date refers to the last day of that month.
Do not use this medicine if you notice signs of deterioration, such as discolouration or broken tablets, are observed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away dispose of medicines no longer required. These measures will help to protect the environment.
6. Contents of the pack and other information
If you or your child take more Ondansetron orodispersible tablets than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.
If you forget to take Ondansetron orodispersible tablets
Do not take a double dose to make up for a forgotten dose.
If you miss a dose and feel sick or vomit, take an Ondansetron orodispersible tablet as soon as possibe and then carry on as before.
If you miss a dose but do not feel sick take the next dose as on the label.
4. possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A few people can be allergic to some medicines; if any of the following side effects come on soon after taking Ondansetron orodispersible tablets, stop taking them and tell your doctor immediately:
- Sudden wheeziness and chest pain or chest tightness
- Swelling of eyelids, face, lips, mouth or tongue
- Skin rash – red spots or hives (skin lumps) anywhere on the body
- Collapse
Other possible side effects:
Very common (may affect more than 1 in 10 people )
-
– Headache.
420 mm
Common (may affect up to 1 in 10 people)
-
– Constipation.
-
– Sensation of warmth or flushing.
Uncommon (may affect up to 1 in 100 people)
-
– Arrhythmias, chest pain with or without ST segment depression, bradycardia.
-
– Asymptomatic increases in liver function tests.
-
– Seizures, movement disorders including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia have been observed without definitive evidence of persistent clinical sequelae.
-
– Hiccups.
-
– Hypotension.
Rare (may affect up to 1 in 1000people)
-
– Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.
-
– Dizziness during i.v. administration, which in most cases is prevented or resolved by lengthening the infusion period.
-
– Transient visual disturbances (eg. blurred vision) during i.v. administration.
Very rare (may affect up to 1 in 10000people) Transient blindness predominantly during intravenous administration
The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.
Strawberry flavour contains sulphur dioxide (E220) which may rarely cause severe hypersensitivity reactions and bronchospasm.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects you can help provide more information on the safety of this medicine.
What Ondansetron orodispersible tablets contains
The active substance is ondansetron. Each orodispersible tablet contains 4 mg or 8 mg ondansetron.
The other ingredients are: aspartame (E951), crospovidone type B, magnesium stearate (E572), microcrystalline cellulose (E460), pharmaburst TM C1, containing mannitol (E421), sorbitol (E420), crospovidone (type A) and colloidal silicon dioxide); strawberrry flavouring, (containing glucose, maltodextrin, gum arabic E414 2.3% and sulphur dioxide E220); sodium stearyl fumarate.
What Ondansetron orodispersible tablets looks like and contents of the pack
Orodispersible tablets.
Ondansetron 4 mg and 8 mg orodispersible tablets
White, flat, round, bevel-edged tablet.
Ondansetron orodispersible tablets are provided in packs of 6 × 1, 10 × 1, 14 × 1, 20 × 1, 30 × 1, 50 × 1, 60 × 1, 100 × 1 tablets in aluminium/ OPA/PVC unit-dose blister pack.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Bluefish Pharmaceuticals AB
P.O. Box 49013
100 28 Stockholm
Sweden
Manufacturer
Sofarimex Industria Qmmica e
Farmaceutica S.A.
Av. das Industrias- Alto do Colaride,
Cacem, 2735–213
Portugal
The package leaflet for the blind and partially sighted in other formats is made available on request.
This medicinal product is authorised in the | |
Member States following names : | of the EEA under the |
Name of the | Name of the medicinal |
Member State | product |
Denmark | Ondansetron Bluefish 4 mg/ 8 mg smeltetabletter |
Finland | Ondansetron Bluefish 4 mg/ 8 mg tabletti, suussa hajoava Ondansetron Bluefish 4 mg/ 8 mg munsonderfallande tabletter |
Germany | Ondansetron Bluefish 4 mg/ 8 mg schmelztabletten |
Norway | Ondansetron Bluefish 4 mg/ 8 mg smeltetabletter |
Poland | Ondansetron Bluefish |
Spain | Ondansetron Bluefish 4 mg/ 8 mg comprimidos bucodispersibles EFG |
Sweden | Ondansetron Bluefish 4 mg/ 8 mg munsonderfallande tabletter |
United Kingdom | Ondansetron 4 mg/ 8 mg orodispersible tablets |
This leaflet was last revised in November 2020
5. how to store ondansetron orodispersible tablets
Keep this medicine out of the sight and reach of children.
Store in the original package in order to protect from light.
Store below 30oC.
uk-mocku
p
1.3.2.CC.1 Pg. 2
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist or nurse.This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet :
What Ondansetron orodispersible tablets is and what it is used for
What you need to know before you take Ondansetron orodispersible tablets
How to take Ondansetron orodispersible tablets
Possible side effects
How to store Ondansetron orodispersible tablets
Contents of the pack and other information
1. What Ondansetron orodispersible tablets are and what it is used for
Ondansetron orodispersible tablet is a fast dissolving tablet when placed on top of the tongue. Ondansetron orodispersible tablets contains ondansetron which belongs to a group of medicines that stop you feeling sick or being sick, so called anti-emetics.
Ondansetron orodispersible tablets may:
– stop the effects of nausea and vomiting caused by cytotoxic chemotherapy in children and adults
– prevent post-operative nausea and vomiting in children and adults
– stop the effects of nausea and vomiting caused by radiotherapy in adults
If you are not sure why they have been prescribed for you, ask your doctor.
2. What you need to know before you take before you take Ondansetron orodispersible tablets
Do not take Ondansetron orodispersible tablets – if you are allergicto ondansetron, or any of the other ingredients of this medicine (listed in section 6).
– if you are taking apomorphine (used to treat Parkinson’s disease).
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Ondansetron orodispersible tablets
– if you are pregnant or likely to become pregnant soon.
– if you are breast-feeding.
– if you have liver disease.
– if you have a blockage in your gut or if you suffer from severe constipation
– if it is children below the age of 2 years or with a body surface of less than 0.6 m2.
Other medicines and Ondansetron orodispersible tablets
Tell your doctor or pharmacist if you are taking,have recently taken or might take any other medicines like phenytoin, carbamazepine, rifampicin, tramadol.
Pregnancy and breast-feeding
Only use Ondansetron orodispersible tablets during the first trimester of pregnancy after discussion with your doctor of the potential benefits and risks to you and your unborn baby of the different treatment options. This is because Ondansetron orodispersible tablets can slightly increase the risk of a baby being born with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). If you are already pregnant, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Ondansetron orodispersible tablet.If you are a woman of childbearing potential you may be advised to use effective contraception.
Ondansetron probably passes into the mother's milk. Therefore it is recommended that mothers taking Ondansetron orodispersible tablets do not breast-feed.
Driving and using machines
Ondansetron orodispersible tablets has no influence on the ability to drive and use machines.